Open Accessibility Menu
Hide

Clinical Trials

Search Clinical Trials
All Clinical Trials
  • Expanded Access Protocol for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Multiple Myeloma

    Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody. For more information about this clinical trial from ClinicalTrials.gov, please click here .

    Continue Reading

    Principal Investigator: Furhan Yunus, M.D.

    Research Nurse: Wendy Blount, RN, MSN

  • Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive Ovarian Cancer

    For information about this trial on ClinicalTrials.gov, please click here .

    Continue Reading

    Principal Investigator: Rodney Rocconi, M.D.

    Research Nurse: Wendy Blount, RN, MSN

  • Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC). Brain Cancer, Non-small Cell Lung Cancer

    NCT02831959 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC). For more information about this trial on ClincialTrials.gov, please click here .

    Continue Reading

    Principal Investigator: John Russell, MD

    Research Nurse: Wendy Blount, RN, MSN

  • Circulating Tumor DNA dynamics in Ovarian Cancer Patients on PARP inhibitor maintenance therapy Ovarian Cancer

    This study will assess tumor response to treatment in patients with Stage III/IV epithelial ovarian cancer, who complete frontline chemotherapy and surgery, and are candidates to undergo PARP inhibition maintenance therapy. Whole blood samples will be drawn at pre-determined time points defined within this protocol for SIGNATERA testing. Patients will be followed for up to two ...

    Continue Reading

    Principal Investigator: Rodney Rocconi, M.D.

    Research Nurse: Wendy Blount, RN, MSN

  • ctDNA Kinetics in Locally Advanced Cervical Cancer Undergoing Primary Chemoradiation Cervical Cancer

    This study will assess tumor response to treatment in patients with locally advanced cervical cancer who are undergoing primary chemoradiation. Whole blood samples will be drawn at pre-determined time points defined within this protocol for SIGNATERA testing. Patients will be followed for up to two (2) years. The SIGNATERA test detects and tracks tumor mutational signature ...

    Continue Reading

    Principal Investigator: Rodney Rocconi, M.D.

    Research Nurse: Wendy Blount, RN, MSN

  • A Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) Lung Cancer

    NCT03924869 A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) Click here to learn more about this trial from ClinicalTrials.gov.

    Continue Reading

    Principal Investigator: Jose Galeas, MD

    Research Nurse: Wendy Blount

Page 1 of 3
1-6 of 13 Results